RecruitingNCT06647459

Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial Fibrillation

Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial


Sponsor

Vanderbilt University Medical Center

Enrollment

200 participants

Start Date

Dec 13, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

To use programmed ventricular stimulation at the time of AF ablation to define the prevalence and mechanism of inducible ventricular tachycardia (VT); pace-mapping to define the site of origin of ventricular arrhythmias; and voltage mapping to define low voltage scar substrate in the basal LV in patients with pathogenic TTN variants compared to genotype-negative controls.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating the risk of dangerous heart rhythm problems (ventricular tachycardia) in people who developed atrial fibrillation (an irregular heart rhythm) early in life and carry a genetic variant linked to heart muscle disease. **You may be eligible if...** - You are 18 years or older - You were diagnosed with atrial fibrillation before age 60 - You are scheduled for a catheter-based ablation procedure for your AF (first-time or repeat) - You have a genetic variant in the TTN gene or another cardiomyopathy-related gene, OR you have been confirmed not to carry such a variant (as a control participant) - You are able to provide written informed consent **You may NOT be eligible if...** - You were diagnosed with a genetic heart muscle disease or arrhythmia syndrome before your AF diagnosis - You have a pacemaker or implantable defibrillator (ICD) - You have had a prior procedure for a different type of dangerous heart rhythm - You have severely reduced heart function (ejection fraction below 20%) - You have a prosthetic mitral or aortic valve, heparin allergy, or prior heart attack Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTEP Study

To use programmed ventricular stimulation at the time of AF ablation to define the prevalence and mechanism of inducible ventricular tachycardia (VT); pace-mapping to define the site of origin of ventricular arrhythmias; and voltage mapping to define low voltage scar substrate in the basal LV in patients with pathogenic TTN variants compared to genotype-negative controls.


Locations(1)

Vanderbilt University Medical Center

Nashville, Tennessee, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06647459


Related Trials